BR0012069A - Composições e métodos para a terapia e diagnóstico de câncer pulmonar - Google Patents

Composições e métodos para a terapia e diagnóstico de câncer pulmonar

Info

Publication number
BR0012069A
BR0012069A BR0012069-3A BR0012069A BR0012069A BR 0012069 A BR0012069 A BR 0012069A BR 0012069 A BR0012069 A BR 0012069A BR 0012069 A BR0012069 A BR 0012069A
Authority
BR
Brazil
Prior art keywords
compositions
diagnosis
therapy
methods
lung cancer
Prior art date
Application number
BR0012069-3A
Other languages
English (en)
Inventor
Tongtong Wang
Chaitanya Bangur
Michael J Lodes
Gary R Fanger
Thomas S Vedvick
Darricj Carter
Mark W Retter
Jane Mannion
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/476,300 external-priority patent/US20030125245A1/en
Priority claimed from US09/589,184 external-priority patent/US6686447B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR0012069A publication Critical patent/BR0012069A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA A TERAPIA E DIAGNóSTICO DE CâNCER PULMONAR". Descreve-se composições e métodos para a terapia e diagnóstico de câncer pulmonar. As composições podem compreender uma ou mais proteínas de tumor pulmonar, suas partes imunogênicas, ou polinucleotídeos que codificam essas partes imunogênicas. Alternativamente, uma composição terapêutica pode compreender uma célula apresentadora de antígeno que expressa uma proteína de tumor pulmonar, ou uma célula T que é específica para células que expressam essa proteína. Essas composições podem ser usadas, por exemplo, para a prevenção e tratamento de doenças, tal como câncer pulmonar. Fornece-se também métodos diagnósticos baseados na detecção de uma proteína de tumor pulmonar, ou do RNAm que codifica essa proteína, em uma amostra.
BR0012069-3A 1999-06-30 2000-06-30 Composições e métodos para a terapia e diagnóstico de câncer pulmonar BR0012069A (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US34649299A 1999-06-30 1999-06-30
US41935699A 1999-10-15 1999-10-15
US46686799A 1999-12-17 1999-12-17
US09/476,300 US20030125245A1 (en) 1999-06-30 1999-12-30 Compositions and methods for therapy and diagnosis of lung cancer
US09/519,642 US6933363B1 (en) 1999-06-30 2000-03-06 Compositions and methods for therapy and diagnosis of lung cancer
US53307700A 2000-03-22 2000-03-22
US54625900A 2000-04-10 2000-04-10
US56040600A 2000-04-27 2000-04-27
US09/589,184 US6686447B1 (en) 1999-06-30 2000-06-05 Compositions and methods for the therapy and diagnosis of lung cancer
PCT/US2000/018061 WO2001000828A2 (en) 1999-06-30 2000-06-30 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (1)

Publication Number Publication Date
BR0012069A true BR0012069A (pt) 2002-08-27

Family

ID=27578819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012069-3A BR0012069A (pt) 1999-06-30 2000-06-30 Composições e métodos para a terapia e diagnóstico de câncer pulmonar

Country Status (15)

Country Link
US (1) US6630574B1 (pt)
EP (1) EP1196565A2 (pt)
JP (1) JP2004500029A (pt)
CN (1) CN1367829A (pt)
AR (1) AR032743A1 (pt)
AU (1) AU769143B2 (pt)
BR (1) BR0012069A (pt)
CA (1) CA2380873A1 (pt)
CZ (1) CZ20014718A3 (pt)
HU (1) HUP0201757A3 (pt)
MX (1) MXPA02000192A (pt)
NO (1) NO20016427L (pt)
NZ (1) NZ516381A (pt)
PL (1) PL354093A1 (pt)
WO (1) WO2001000828A2 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1240198A4 (en) * 1999-10-19 2003-11-05 Millennium Pharm Inc GENES ENCODING PROTEINS WITH PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER APPLICATIONS
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6902890B1 (en) 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001036644A2 (en) * 1999-11-18 2001-05-25 Curagen Corporation Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
US7005499B1 (en) 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
US20020038012A1 (en) * 2000-02-22 2002-03-28 Gregory Donoho Novel human regulatory protein and polynucleotides encoding the same
ATE352311T1 (de) * 2000-02-25 2007-02-15 Ucb Sa Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
US20030143654A1 (en) * 2000-05-12 2003-07-31 Matthias Grell F-box containing protein
CA2412211A1 (en) * 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1343886A2 (en) * 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002018584A2 (en) * 2000-09-01 2002-03-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Xage-1, a gene expressed in multiple cancers, and uses thereof
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US20040121313A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in organs for transplantation
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
EP1516049A4 (en) * 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
AU2002356522A1 (en) * 2001-09-04 2003-04-07 Bristol-Myers Squibb Company Polynucleotide encoding adapter protein, pmn29
WO2003046165A1 (en) * 2001-11-26 2003-06-05 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
EP1578399A4 (en) 2002-12-06 2007-11-28 Isis Pharmaceuticals Inc METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND BEETS
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
WO2005014818A1 (ja) 2003-08-08 2005-02-17 Perseus Proteomics Inc. 癌高発現遺伝子
US7087733B2 (en) * 2003-09-02 2006-08-08 Ken-Shwo Dai Human ARL-related gene variants associated with cancers
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
JP4913590B2 (ja) 2004-03-31 2012-04-11 株式会社ペルセウスプロテオミクス 抗ｒｏｂｏ１抗体を用いる癌の診断および治療
WO2005117270A2 (en) 2004-05-24 2005-12-08 Isis Pharmaceuticals, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
NZ555571A (en) * 2004-12-06 2009-02-28 Sciclone Pharmaceuticals Inc Alpha thymosin peptides as cancer vaccine adjuvants
CA2600184A1 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
AU2006272776B2 (en) 2005-07-21 2012-01-19 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
JP5150855B2 (ja) * 2005-07-29 2013-02-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法
AU2007353877B2 (en) 2006-09-14 2012-07-19 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP2126132B1 (en) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Methods for rapid foresnsic dna analysis
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
SG183698A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
EP2349549B1 (en) 2008-09-16 2012-07-18 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, and system
EP2344893B1 (en) 2008-09-16 2014-10-15 Ibis Biosciences, Inc. Microplate handling systems and methods
EP2396803A4 (en) 2009-02-12 2016-10-26 Ibis Biosciences Inc IONIZATION PROBE ASSEMBLIES
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
WO2011008971A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
EP2488656B1 (en) 2009-10-15 2015-06-03 Ibis Biosciences, Inc. Multiple displacement amplification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
MX370265B (es) * 2012-05-25 2019-12-09 Cellectis Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
CN103212077B (zh) * 2013-04-09 2015-09-23 梅林� Erbin抑制剂在制备抗肿瘤药物中的应用
ES2686631T3 (es) * 2014-01-05 2018-10-18 Biomirna Holdings Ltd. Determinaciones de cáncer de pulmón utilizando relaciones de miARN
WO2022246204A2 (en) * 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Compounds for reducing ptbp1 expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
WO1997033993A1 (en) * 1996-03-15 1997-09-18 Sagami Chemical Research Center Human membrane antigen tm4 superfamily protein and dna encoding this protein
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
EP0972022A2 (en) * 1997-01-21 2000-01-19 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof
AU9645598A (en) 1997-10-22 1999-05-10 Helix Research Institute Method for screening full-length cdna clones
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
WO2000021990A1 (en) 1998-10-15 2000-04-20 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000055375A1 (en) 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins

Also Published As

Publication number Publication date
NO20016427D0 (no) 2001-12-28
CN1367829A (zh) 2002-09-04
JP2004500029A (ja) 2004-01-08
CA2380873A1 (en) 2001-01-04
WO2001000828A2 (en) 2001-01-04
AR032743A1 (es) 2003-11-26
NZ516381A (en) 2004-03-26
WO2001000828A3 (en) 2001-08-02
NO20016427L (no) 2002-02-25
HUP0201757A3 (en) 2010-01-28
US6630574B1 (en) 2003-10-07
CZ20014718A3 (cs) 2003-01-15
EP1196565A2 (en) 2002-04-17
AU769143B2 (en) 2004-01-15
HUP0201757A2 (en) 2002-09-28
PL354093A1 (en) 2003-12-29
MXPA02000192A (es) 2004-08-12
AU5902700A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
CO5690564A2 (es) Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]